Clinical Trials Logo

Leukemia, Erythroblastic, Acute clinical trials

View clinical trials related to Leukemia, Erythroblastic, Acute.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04083170 Terminated - Clinical trials for Acute Myeloid Leukemia

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total body irradiation is a type of whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood transplant with dilanubicel may help to kill any cancer cells that are in the body and make room in the patient's bone marrow for new stem cells to grow and reduce the risk of infection.

NCT ID: NCT02105116 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

AML Therapy With Irradiated Allogeneic Cells

Start date: February 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR after the standard induction chemotherapy are eligible for the experimental therapy (irradiated haploidentical cells).

NCT ID: NCT02049801 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162, cytarabine, and idarubicin may be an effective treatment for acute myeloid leukemia.

NCT ID: NCT02030405 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02029417 Terminated - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: July 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia. Omacetaxine mepesuccinate, cytarabine, and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01904643 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: February 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide and combination chemotherapy may be an effective treatment for acute myeloid leukemia.

NCT ID: NCT01849276 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

Start date: March 11, 2015
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine if metformin in combination with cytarabine is safe and effective. Participants in this research study have acute myeloid leukemia (AML) that has come back after initial treatment or has not gone away with initial therapy.There is evidence that metformin directly kills leukemia cells. Laboratory data have also shown that combinations of metformin with cytarabine are more efficient than each agent alone in killing leukemia cells in the laboratory.

NCT ID: NCT01801046 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

Start date: March 6, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect)

NCT ID: NCT01550185 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse

NCT ID: NCT01521936 Terminated - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This partially randomized phase II trial studies the side effects and best way to give and best dose of cholecalciferol in treating patients with acute myeloid leukemia (AML) undergoing intensive induction chemotherapy. Cholecalciferol may help improve the outcome of patients with AML undergoing intensive chemotherapy